Working… Menu

Eribulin Plus Gemcitabine (EG) vs Paclitaxel Plus Gemcitabine (PG) in HER2-Negative Metastatic Breast Cancer (EG_PG)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02263495
Recruitment Status : Completed
First Posted : October 13, 2014
Last Update Posted : July 14, 2020
Eisai Inc.
Dong-A ST Co., Ltd.
Samyang Biopharmaceuticals Corporation
Information provided by (Responsible Party):
Kyung Hae Jung, Asan Medical Center